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Abstract
In cats, the incidence of obesity and diabetes is increasing, and little is known about speciﬁc aspects of the endocrine control of food intake in this species.
Recent data suggest that ghrelin has an important role in the control of insulin secretion and vice versa, but this role has never been demonstrated in cats.
Here we aimed to improve our understanding about the relationship between insulin, amylin and ghrelin secretion in response to a nutrient load in over-
weight cats. After a 16 h fast, weekly, six overweight male cats underwent randomly one of the four testing sessions: saline, glucose, arginine and TAG. All
solutions were isoenergetic and isovolumic, and were injected intravenously as a bolus. Glucose, insulin, acylated ghrelin (AG), amylin and prolactin were
assayed in plasma before and 10, 20, 40, 60, 80 and 100 min after the nutrient load. A linear mixed-effects model was used to assess the effect of bolus and
time on the parameters. A parenteral bolus of glucose or arginine increased insulin and ghrelin concentrations in cats. Except for with the TAG bolus, no
suppression of ghrelin was observed. The absence of AG suppression after the intravenous load of arginine and glucose may suggest: (1) that some nutri-
ents do not promote satiation in overweight cats; or that (2) AG may be involved in non-homeostatic consumption mechanisms. However, the role of
ghrelin in food reward remains to be assessed in cats.
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The popularity of the cat as a pet has dramatically increased in
the last 20 years. This success has been associated with many
changes for feline life: neutering, decreased physical activity
and indoor conﬁnement. In parallel, the typical diet of pet
cats has changed from a carnivorous to an omnivorous regi-
men since many cats are now fed with very palatable high-
energy-dense commercial dry foods. All of these modiﬁcations
have been recognised to increase food intake and decrease
energy expenditure, which may eventually lead to obesity and
type 2 diabetes mellitus(1). Whether high-carbohydrate diets
are a risk factor for obesity and type 2 diabetes mellitus
remains an unsolved question at the present time(1,2).
In cats, the main source for blood glucose is gluconeogen-
esis from amino acids(3) and amino acids are strong stimulators
of pancreatic hormone release, especially insulin(4). Although
cats are strict carnivores, they appear to be quite efﬁcient at
digesting processed starches, even though they may have a lim-
ited ability to metabolise some mono- and disaccharides(5–7).
Cats have minimal activity of hepatic glycogen synthase(8)
and a lower ability than dogs to remove glucose from the
bloodstream after a meal(9).
In mammals, many signalling molecules are involved in the
control of food intake, glucose homeostasis and energy
expenditure(10). Insulin is the traditional hormone cited for
Abbreviations: AG, acylated ghrelin; ARG, arginine; BFM, body fat mass; BW, body weight; ME, metabolisable energy; PRL, prolactin.
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the control of blood glucose concentration. After a meal,
β-cells of the pancreas secrete insulin in response to a rise in
blood glucose, but this response is also proportional to body
fat(10). The role of insulin is not limited to blood glucose regu-
lation. Other metabolic effects of insulin include stimulation of
the incorporation of amino acids into proteins, and inhibition
of the release of NEFA from adipose tissue(11). Moreover,
insulin acts peripherally to increase energy storage, and central-
ly to reduce food intake and to increase energy expenditure(10).
Similarly to leptin, insulin is considered to be an adiposity sig-
nal because it is secreted in proportion to body fat mass
(BFM) and inﬂuences food intake and body weight (BW)(10).
Amylin is also considered to be an adiposity factor(10). This
hormone is co-secreted with insulin. It delays gastric emptying
and reduces food intake. Amylin has also been shown to
increase the anorexic effect of other hormones such as chole-
cystokinin, insulin and leptin(12–15). Insulin and amylin have
complementary effects on glucose metabolism and food
intake. During the postprandial period, insulin stimulates per-
ipheral glucose uptake, whereas amylin controls glucose
appearance into the bloodstream by the control of gastric
emptying, suppression of postprandial glucagon secretion
and by inducing satiation(15). In conditions associated with
insulin resistance such as obesity, amylin levels are often
increased in parallel with insulin. It has been shown that
chronic exposure to amylin decreases food intake and BW
gain(16); further, even in chronic hyperamylinaemia amylin sig-
nalling is not down-regulated, and amylin is able to suppress
food intake(16).
Presently, only one peripherally released orexigenic hormone
has been discovered: ghrelin. Ghrelin is mainly but not only
secreted from the stomach, and circulating levels are higher
during fasting. Two major forms have been recognised(17): acy-
lated ghrelin (AG) and deacylated ghrelin. Both forms control
insulin secretion and glucose metabolism. AG has traditionally
been considered to be a hunger signal, being sensed in the cen-
tral nervous system; accordingly, exogenous ghrelin has been
reported to stimulate food intake, BW gain and adiposity
when administered peripherally or centrally to rodents(18).
Ghrelin also stimulates prolactin (PRL) release(19). PRL is
involved in the control of food intake, especially but not
exclusively during periods of reproduction(20). In rats, PRL
receptors are expressed on oxytocin neurons in the paraven-
tricular hypothalamus(21), neurons implicated in food intake
and energy metabolism. PRL receptor activation is also
involved in the development of islet cells of the pancreas
and in the increase in islet cell mass during pregnancy. In
brown adipose tissue, the effects of PRL are numerous(22):
PRL stimulates proinsulin gene expression, and, in the pres-
ence of insulin, increases Ob (leptin) gene expression as well
as leptin release.
In a recent study, we provided the ﬁrst results on postpran-
dial AG concentrations in cats and underlined several discrep-
ancies between cats and previous reports in human subjects
and rodents(23). In that study, we compared the effect of
three meals with different protein:fat ratios on the postprandial
concentrations of insulin, AG and amylin in lean and obese
cats. We showed that food intake did not differ among
diets, but, interestingly, obese cats consumed signiﬁcantly
less food than lean cats. Obesity induced signiﬁcantly higher
postprandial responses of blood glucose and ghrelin, but
had no effect on insulin and amylin variations. The main effect
on the different parameters was related to the protein content
of the diet. We unexpectedly observed that AG concentrations
rose signiﬁcantly after a meal in cats. Nevertheless, with regard
to the total amount of food spontaneously consumed with the
three diets, the highest postprandial AG was not associated
with higher food intake.
As very few studies have been conducted in cats, further
investigation was required for a better understanding of the
effect of ghrelin. In our previous study, we questioned why
AG was not suppressed after meal ingestion. We therefore
decided to use each nutrient separately to depict the time
course of AG concentration after an intravenous load. The
relationship between insulin, amylin and ghrelin secretion
and their relevant roles in glucose metabolism in overweight
cats were considered here. We hypothesised that: (1) AG con-
centration would promptly decrease in cats after a nutrient
load (glucose, arginine (ARG) or NEFA); and (2) there was
an inverse relationship between AG and insulin concentrations.
Materials and methods
Animals
A group of six overweight neutered domestic short hair adult
male cats from different genetic backgrounds (body condition
score 7 on a nine-point scale) were included in the study. Mean
BW was 6·2 (SD 0·5) kg and mean age was 6·9 (SD 1·8) years.
Before the start of the study, the cats were group housed and
fed free choice for at least 2 months the same balanced main-
tenance diet (Neutered Cat, Young Adult; Royal Canin).
During the study, the cats were weighed weekly and body
condition score was noted. A clinical and biochemistry examin-
ation was performed before the cats were included in the study.
Protocol
The experimental protocol was reviewed and approved by the
Royal Canin Committee for Animal Ethics and Welfare.
Husbandry and use of the cats were in accordance with current
French and international regulations concerning animals used
for experiments (authorisation no. D 00 66 894). Particular
attention was paid to the guidelines designed to promoting
well-being of the cats in a safe, enriched environment.
Except during periods of handling during the study, the cats
were kept together in a large cattery with inside and outside
areas. Room lighting consisted of 12 h light and dark periods
from 06.00 to 18.00 hours and the inside temperature ranged
from 18°C to 21°C.
Methods
After the period of adaptation on the same balanced cat food,
cats were randomly assigned successively to one of the four
intravenous solutions tested: saline, ARG, fatty acids or glucose.
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The experimental procedures were chosen to limit stress and
to promote safe handling of the cats. The day before each test,
cats were anaesthetised using the following protocol: atropine
sulfate (0·05 mg/kg subcutaneously) and, 15 min later, a mix-
ture of tiletamine/zolazepam (10 mg/kg intramuscularly).
A 6 cm sterile catheter (Leader-Cath; Vygon) was then inserted
in the jugular vein using the Seldinger method and sutured to
the skin (3/0 Prolene; Ethicon) to allow painless blood sam-
pling. Catheter patency was maintained by ﬂushing with a
heparinised (50 IU/ml) physiological saline solution. A head
cone was placed to prevent the catheter from being torn off
during the night.
After a 16 h fast, all cats underwent one of the following
four testing sessions in a random order: (1) saline; (2)
D-glucose (G30; B. Braun Medical SA); (3) ARG (L-arginine
hydrochloride 21 %; B. Braun Melsungen AG); and (4)
TAG from soya oil (Intralipid 20 %; Fresenius Kabi). The
cats underwent one test per week for 4 weeks. All solutions
were injected intravenously as a bolus via a separate catheter
placed in the cephalic vein. For all the tests, the amount
injected represented 4 % of daily maintenance metabolic
energy requirement for an adult overweight cat according to
the National Research Council(24) (544 × BW0·4 kJ (130 ×
BW0·4 kcal) metabolisable energy (ME)/d) (isoenergetic
tests). The total volume injected was adjusted to be identical
for each test (isovolumic tests). As the largest calculated vol-
ume was for L-arginine, all the other volumes were adjusted
on its basis to provide isoenergetic loads. For example, for a
6 kg cat, the volume of each solution was 8·3 ml, 11·9 ml
and 5·5 ml for D-glucose, ARG and TAG, respectively. All
the volumes were adjusted to 11·9 ml for all the solutions,
including saline.
As it has been shown that oral infusion of glucose can de-
crease the plasma concentration of ghrelin as soon as 30 min
after ingestion in human subjects and in rats(25), blood samples
were taken before (10 min before each bolus = baseline) and
10, 20, 40, 60, 80 and 100 min after injection to depict the
acute effect of the nutrient load on glucose, insulin, AG, amy-
lin and PRL concentrations. All blood samples were handled
similarly: whole blood (2 ml) was collected through the
jugular catheter and placed in tubes containing EDTA+ apro-
tinin (0·6 trypsin inhibitor units/ml of whole blood,
RK-APRO; Phoenix Pharmaceuticals Inc.) for plasma collec-
tion. Immediately after collection, the tubes were preserved on
ice (at about 0–4°C) until centrifugation (< 30 min). The tubes
were centrifuged (Sigma 2 K 15; Sigma Laborzentrifugen
GmbH) at 3000 g for 10 min at 4°C. The plasma for hormone
measurements was stored at <−80°C pending analysis.
Analyses
Body composition was determined from isotope dilution of
2H2O at the start of the study
(23). For hormone analyses, com-
mercially available kits were used. All assays had previously
been validated for use in cats; the assay procedures were per-
formed according to the manufacturers’ instructions. Insulin
was assayed in duplicate using the porcine insulin RIA
kit (catalogue no. PI-12 K-85 K; Linco Research, Inc.)(23).
Amylin was assayed in duplicate with a RIA kit speciﬁcally
developed for cats (catalogue no. RK-017-01; Phoenix
Pharmaceuticals, Inc.)(23). Plasma ghrelin levels were measured
in duplicate with a human active ghrelin RIA kit from Linco
Research (catalogue no. GHRA-88HK) that shows signiﬁcant
cross-reactivity with feline ghrelin(23). PRL was assayed in trip-
licate as previously described in cats(26).
Statistical analysis
Considering the large variation in baseline data (Table 1), the
results were calculated as change from baseline for each
respective cat. A linear mixed-effects model was used to assess
the effect of body composition (df = 1), bolus (df = 3) and
time (df = 4) on the measured parameters. The ﬁxed effects
were the type of bolus (glucose, ARG, TAG or saline) and
time, and the random effect corresponded to individuals
(cats). The normality of the residuals was checked for each
model to assess the validity of the test.
When appropriate (P < 0·05), the linear mixed-effects model
was followed by a Tukey’s post hoc test to assess the effect of
bolus, time or BFM on the measured parameters. Pearson’s
correlation tests were also used to measure the strength of
association among data. Data were expressed as mean values
with their standard errors, and P < 0·05 was considered signiﬁ-
cant. All statistical analyses were performed with XLstat-Pro
2011 software (Addinsoft SARL).
Results
All cats remained healthy during the study on the basis of a
weekly physical examination, the lack of any clinical signs
and biochemistry analysis. Mean BFM was 34·5 (SD 3·3) %.
Baseline concentrations
Baseline concentrations are presented in Table 1. Mean baseline
concentrations of insulin, amylin, PRL and ghrelin did not differ
between cats. BFM and blood glucose were positively correlated
(P= 0·008) (data not shown). BFM was also signiﬁcantly nega-
tively correlated with mean PRL concentrations (BFM< 35 %:
mean concentration = 50·8 ng/ml; BFM> 35 %: mean concen-
tration = 24·7 ng/ml; P= 0·001) (data not shown).
Table 1. Baseline concentrations for glycaemia, insulin, amylin and
acylated ghrelin*
(Mean, minimum and maximum values and standard errors)
Cats ×
testing
sessions (n) Mean Minimum Maximum SEM
Blood glucose
(mmol/l)
6 × 4 5·2 4·2 7·6 0·15
Insulin (pmol/l) 6 × 4 196·0 55·6 444·5 19·4
Amylin (pg/ml) 6 × 4 50·5 27·0 92·4 3·4
Acylated ghrelin
(pg/ml)
6 × 4 43·4 26·4 79·4 3·0
Prolactin (ng/ml) 6 × 4 40·3 15·4 93·6 3·8
* Baseline concentrations were assayed in plasma samples before the administration
of each bolus. Mean baseline concentrations did not differ between cats.
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Blood glucose
Saline administration did not signiﬁcantly modify blood glu-
cose level (Fig. 1).
As expected, glycaemia was the highest after the glucose
bolus (P < 0·0001) (Fig. 1), showing the main increase 10
min after injection (+15·1 (SEM 1·5) mmol/l; P < 0·001),
then slowly decreasing over time. After 100 min, blood glu-
cose had not returned to its baseline concentration (P =
0·021). Despite the low energy load of the intravenous infu-
sion (4 % of daily maintenance metabolic energy requirement),
the amplitude of glycaemic excursions was higher than after a
meal for cats(23).
Overall glycaemia was increased after ARG administration
(P< 0·0001) (Fig. 1). There was a small, transient but signiﬁ-
cant rise of glycaemia from baseline10 min after the ARG
bolus (P < 0·001), then a rapid decrease to baseline: as soon
as 20 min after injection, glycaemia returned to baseline
(P= 0·785). The observed variations in blood glucose were
small and remained similar to postprandial concentrations.
After TAG injection, in general, blood glucose varied sig-
niﬁcantly from baseline (P = 0·001). Blood glucose concentra-
tion was higher than baseline 100 min after TAG injection
(Fig. 1).
Insulin concentration
The saline bolus did not signiﬁcantly affect the concentrations
of insulin during the 100 min following its administration
(Fig. 2).
After the glucose bolus and in response to the signiﬁcant
increase in glycaemia, there was a signiﬁcant increase in insulin
concentrations (P= 0·032) which remained high throughout
the study period (Fig. 2). After 100 min, the mean insulin vari-
ation was + 313 pmol/l but was not signiﬁcantly different
from baseline (P= 0·074).
At 10 min after ARG injection, insulin concentration was sig-
niﬁcantly increased from baseline (P< 0·0001), and then it
decreased promptly to reach baseline levels at 20 min (Fig. 2).
TAG induced a signiﬁcant prompt but transient increase in
insulin (P= 0·033), peaking at 20 min (P = 0·027) and at 40
min (P = 0·027), and then insulin concentration returned to
baseline (Fig. 2). With the TAG bolus, time course of insulin
concentration was inﬂuenced by the BFM of the cats (P =
0·0001) because cats with a BFM < 35 % showed the highest
mean increase ( + 83·3 pmol/l v. −19·4 pmol/l for cats with a
BFM> 35 %) (data not shown).
Acylated ghrelin concentrations
Saline did not signiﬁcantly affect the concentrations of AG
during the 100 min following its administration (Fig. 3).
Plasma AG signiﬁcantly increased from baseline over time
(P = 0·05) (Fig. 3) after glucose. The concentration of AG
was signiﬁcantly increased at 80 min (P = 0·025) and 100
min (P = 0·023).
The acute administration of ARG was followed by a signiﬁ-
cant increase in AG concentrations from baseline (P < 0·0001)
that was preceded by a transient but non-signiﬁcant reduction
in AG concentration at 10 min (Fig. 3). The concentrations of
AG were signiﬁcantly higher than baseline at 60 min (P =
0·001), 80 min (P = 0·002) and 100 min (P = 0·027) and did
not return to baseline values during the duration of the study.
Fig. 1. Glucose variations from baseline after saline (□), glucose (■), arginine (≡) and TAG (░) intravenous loads. Values are means, with standard errors repre-
sented by vertical bars. There was no significant variation in concentrations within the test after the saline bolus. The concentration of glucose was significantly
increased from baseline 10 min (P < 0·0001), 20 min (P < 0·0001), 40 min (P < 0·0001), 60 min (P < 0·0001), 80 min (P = 0·0001) and 100 min (P = 0·021) after intra-
venous glucose injection. The concentration of glucose was significantly higher than baseline 10 min (P < 0·0001) after the arginine bolus injection. The concentration
of glucose was significantly higher than baseline 100 min (P < 0·0001) after the TAG bolus injection. Mean value was significantly different from that at baseline:
*P < 0·05, ***P < 0·001.
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After TAG administration, there was a signiﬁcant progres-
sive decrease in AG concentrations (P = 0·021) (Fig. 3).
AG concentrations were signiﬁcantly lower than baseline at
60 min (P = 0·013) and 80 min (P = 0·001). Such as for insulin
concentrations, time course of AG was modiﬁed according
to the BFM of the cats (P = 0·002); cats with a BFM >
35 % showed the highest mean decrease (−11·7 pg/ml v.
−0·9 pg/ml for cats with a BFM < 35 %) (data not shown).
Fig. 3. Acylated ghrelin (AG) variations from baseline after saline (△), glucose (○), arginine (•) and TAG (▴) intravenous loads. Values are means, with standard
errors represented by vertical bars. There was no significant variation in concentrations within the test after the saline bolus. The concentration of AG was significantly
increased from baseline 80 min (P = 0·025) and 100 min (P = 0·023) after glucose administration. AG significantly increased from baseline at 60 min (P = 0·001), 80
min (P = 0·002) and 100 min (P = 0·027) after arginine administration. AG was significantly lower than baseline at 60 min (P = 0·013) and 80 min (P = 0·001) after the
TAG bolus injection. Mean value was significantly different from that at baseline: *P < 0·05, **P < 0·01.
Fig. 2. Insulin variations from baseline after saline (△), glucose (○), arginine (•) and TAG (▴) intravenous loads. Values are means, with standard errors repre-
sented by vertical bars. There was no significant variation in concentrations within the test after the saline bolus. The concentration of insulin was significantly
increased from baseline 20 min (P = 0·004), 40 min (P = 0·004), 60 min (P = 0·003) and 80 min (P = 0·003) after glucose administration. Insulin was significantly
increased from baseline 10 min (P < 0·0001) after the arginine bolus injection. Insulin concentration increased significantly from baseline at 10 min (P = 0·027)
and 20 min (P = 0·027) after the TAG bolus injection. Mean value was significantly different from that at baseline: *P < 0·05, **P < 0·01, ***P < 0·001.
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Amylin concentrations
Amylin concentrations were affected by both the type of bolus
(P= 0·003) (Fig. 4) and the BFM of the cats (P = 0·048).
There was a signiﬁcant increase in amylin concentration at
20 min (P = 0·027), 40 min (P= 0·027) and 60 min (P =
0·002) after the TAG bolus. Amylin concentrations were the
highest for cats with a BFM < 35 % (mean variation +7·1
pg/ml) whereas cats with a BFM > 35 % showed the lowest
variations (mean variation −0·8 pg/ml) (data not shown).
However, there was no signiﬁcant variation in amylin
Fig. 5. Prolactin variations from baseline after saline (△), glucose (○), arginine (•) and TAG (▴) intravenous loads. Values are means, with standard errors repre-
sented by vertical bars. There was no significant variation from baseline with time but overall concentrations were the lowest after the arginine load (P = 0·002).
Fig. 4. Amylin variations from baseline after saline (△), glucose (○), arginine (•) and TAG (▴) intravenous loads. Values are means, with standard errors repre-
sented by vertical bars. There was no significant variation in amylin concentration during the saline, glucose and arginine tests. Amylin variations were significantly
higher than baseline after the TAG bolus at 20 min (P = 0·027), 40 min (P = 0·027) and 60 min (P = 0·002). Mean value was significantly different from that at baseline:
*P < 0·05, **P < 0·01.
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concentration with time for the saline, ARG and glucose tests,
despite signiﬁcant increases in insulin concentrations after glu-
cose and ARG administration (Fig. 4).
Prolactin concentrations
Post-test PRL concentrations were affected by the type of
nutrient (P= 0·002) but not by BFM or time. Mean concen-
trations were lowest during the ARG test (mean variation
−6·5 ng/ml) whereas mean variations were not different among
the saline (mean variation −0·2 ng/ml), glucose (mean variation
0·2 ng/ml) and TAG (mean variation 2·2 ng/ml) tests (Fig. 5).
Pearson’s correlations among data
When pooling all data, the Pearson’s correlation test showed a
signiﬁcant relationship between glucose and insulin (P<
0·0001; r 0·48) and between amylin and insulin (P = 0·01;
r 0·21). PRL was correlated with the following parameters:
amylin (P= 0·034; r 0·16); insulin (P = 0·029; r 0·17); and gly-
caemia (P = 0·0008; r 0·25). Nevertheless, except for insulin
and glucose, the correlations were weak.
AUC
AUC were calculated for glucose, insulin, amylin and ghrelin
(Table 2) from baseline concentrations.
The AUC for glucose was signiﬁcantly higher after glucose
injection and did not differ between the saline, ARG and TAG
tests (P = 0·012). The AUC for insulin differed signiﬁcantly
between the four tests and was the highest after glucose
administration (saline 1037 (SEM 1952) pmol/l × min < TAG
6618 (SEM 5809) pmol/l × min < ARG 14173 (SEM 7522)
pmol/l × min < glucose 38008 (SEM 15860) pmol/l × min;
P= 0·002). There was no statistical difference for the AUC
for amylin and the AUC for ghrelin due to great variations
in concentrations among cats.
Discussion
The present study was intended to examine whether nutrients
affect variations in glucose, insulin, amylin, AG and PRL in
overweight cats, all these hormones being signals for the con-
trol of glucose metabolism, food intake and BW. To our
knowledge, this is the ﬁrst time that the relationship between
the intravenous load of a single nutrient and endocrine factors
involved in metabolism and appetite control has been investi-
gated in cats. The present results showed that responses were
inﬂuenced by the type of nutrient.
In human subjects and rodents, studies examining the effect
of a single nutrient on ghrelin secretion are conﬂicting. Ghrelin
secretion is affected by the class of nutrient, but it is not clear
which factors are directly involved in the control of its secre-
tion. In humans and rats, Gil-Campos et al.(18) found that glu-
cose and amino acids suppressed ghrelin secretion more
rapidly and strongly than lipids. However, conversely, in nor-
mal human subjects, Broglio et al.(27) showed no ghrelin sup-
pression after an ARG or NEFA load. In the present study,
no suppression but, rather surprisingly, an increase was
observed after the glucose or the ARG tests in cats. The
TAG bolus induced a slow AG decrease from baseline for
80 min then an increase to reach baseline again.
In our cats, the AG response might be related to the mag-
nitude of the glycaemic response: there was a notable rise in
AG concentration after the glucose or ARG boluses, without
any signiﬁcant suppression of its concentrations. After TAG
injection, the small variations of glycaemia from baseline
were accompanied by a slow decline in AG concentrations.
Table 2. AUC for blood glucose, insulin, amylin and acylated ghrelin*
(Mean values and standard deviations)
Mean SD Test effect (P)
AUC glucose (mmol/l × min) 0·012
Saline 43·5a 24·6
Glucose test 838·5b 165·6
Arginine test 34·1a 13·4
TAG test 30·1a 16·7
AUC insulin (pmol/l × min) 0·002
Saline 1037a 1952
Glucose test 38008d 15860
Arginine test 14173c 7522
TAG test 6618b 5809
AUC amylin (pg/ml ×min) NS
Saline 296·0 275·3
Glucose test 955·7 1269·1
Arginine test 650·4 808·8
TAG test 1690·5 1773·3
AUC acylated ghrelin (pg/ml ×min) NS
Saline 671·8 645·9
Glucose test 1435·0 1304·8
Arginine test 2876·3 1784·6
TAG test 96·5 96·0
* The AUC for glucose was significantly higher after the glucose bolus and did not differ between the saline, arginine and TAG tests. The AUC for insulin differed significantly
between the four tests and was the highest after the glucose bolus. There was no statistical difference for the AUC for amylin and the AUC for ghrelin.
a,b,c,d Mean values within an outcome with unlike superscript letters were significantly different (P < 0·05).
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A strong positive association was previously demonstrated
between 24 h mean peripheral concentrations of AG and post-
prandial glucose in human subjects(28) and the present results
suggest a similar mechanism in cats.
Interestingly, about 10 years ago, Tschöp et al.(29) demon-
strated that ghrelin induces a switch from lipid to carbohydrate
as the fuel for energy production. Using indirect calorimetry,
they showed that a single subcutaneous injection of ghrelin
signiﬁcantly increased the respiratory quotient of the rats,
indicating a higher carbohydrate and a reduced fat metabolic
utilisation, without any changes in energy expenditure and
locomotor activity. This speciﬁc ghrelin effect might be inde-
pendent from growth hormone or neuropeptide Y release. If
such a mechanism existed in cats, it could be supposed that
the rise in AG concentration after glucose or ARG injection
might be a physiological response to promote the metabolic
utilisation of glucose as the fuel for energy production.
Nevertheless, when insulin and AG variations were consid-
ered together, a glucose bolus induced an increase in both hor-
mones. Conversely, an ARG or TAG bolus induced an inverse
relationship in insulin and AG variations: ﬁrst an increase in
insulin and a decrease in AG – notably, the decrease was non-
signiﬁcant after the ARG load – and then when insulin
decreased to baseline, an increase in AG was observed.
An inverse relationship between ghrelin and insulin has been
previously observed in healthy human subjects(27). In this
study, authors also suggested: (1) the ability of insulin to sup-
press circulating ghrelin independently from changes in gly-
caemia; and (2) the ability of ghrelin to decrease insulin
concentration and to increase blood glucose by different path-
ways. In addition, ghrelin is known to play a role in insulin sen-
sitivity(17). Hence, these data indicate that AG may be a strong
regulator of plasma insulin and glucose level in healthy
humans(30,31) and the results presented here support the idea
that a similar mechanism of regulation of blood glucose in
cats might be instrumental.
In a previous study, we measured the variations of insulin
and AG after the intake of different commercial diets(23).
We used a high-protein/medium-fat diet, a high-fat diet and
a balanced diet. During the test meal (which corresponded
to 50 % of the daily ration (35 g)), the cats ingested 16·1 g pro-
teins, 4·2 g fats and 6·0 g starch with the high-protein/
medium-fat diet, 10·5 g proteins, 7·7 g fats and 8·5 g starch
with the high-fat diet and 9·5 g proteins, 4·6 g fats and 11·6
g starch with the balanced diet. In this study, no suppression
of AG was observed after the meal and the magnitude of insu-
lin variations in the postprandial state for all three diets was
lower than in the present study.
The results were revisited to highlight a possible relationship
between insulin and ghrelin in the postprandial period in over-
weight cats. For the high-fat diet (46 % ME from fat), the
response to the test meal also showed an inverse relationship
between insulin and AG. A small transient increase in insulin
concentration was observed immediately after the test meal
(P= 0·006) but insulin concentration returned to baseline as
soon as 30 min after the meal. The decrease in insulin concen-
tration coincided with an increase in AG concentrations and
AG concentrations increased to values higher than baseline
60 min after meal ingestion (P = 0·023). For the balanced
diet (35 % ME from carbohydrates), no clear inverse relation-
ship appeared, probably due to the balance of proteins, starch
and fat in the diet. Nevertheless, AG concentrations were sig-
niﬁcantly increased 60 min (P = 0·038) and 100 min (P =
0·033) after meal ingestion, suggesting that cats might not
obtain a satisfactory level of satiation after such meals.
However, satiation is a complex process and many other fac-
tors are involved in this physiological pathway.
With the ‘high-protein/medium-fat’ diet (48 % ME from
proteins and 28 % ME from fat), we observed an inverse rela-
tionship between insulin and AG, thus depicting a very similar
response to the present ARG test(23). Nevertheless, the con-
centration of AG did not vary signiﬁcantly with time from
baseline in the previous study. The response to the test meal
was probably the consequence of the high level of proteins
in the diet. In a recent study, Wei et al.(32) compared the effect
of a high-protein diet (47 % ME from protein) and a balanced
diet (27 % ME from protein) on energy balance in ad
libitum-fed obese cats. They found no decrease in food intake
in response to the high-protein diet and an increase in energy
intake. This result supports our previous observation on AG
response after a meal showing no clear suppression of the hor-
monal concentrations during the postprandial state. Another
study also reported that high-protein diets do not induce a
decrease in energy intake in cats(33). This result seems to
contradict the statement that protein and amino acids are
involved in satiation signalling in cats. In human subjects
and in rodents, dietary proteins have a clear inﬂuence on the
release of the main anorexigenic gut peptides(34,35) and, like-
wise, act to reduce food intake. In human subjects, Long
et al.(36) demonstrated that the satiating efﬁciency of proteins
was related to the usual level of protein intake in the diet.
They found that the magnitude of satiation decline was related
to a higher capacity to oxidise amino acids. In opposition,
Russell et al.(33) compared protein oxidation in cats fed a
medium-protein diet (35 % ME from protein; 62 % ME
from fat) or a high-protein diet (52 % ME from protein;
45 % ME from fat). When the amount of dietary protein
increased, protein oxidation also increased signiﬁcantly while
fat oxidation decreased. In their study, the amount of food
intake was higher with the high-protein diet (230 g/d) than
with the control food (190 g/d) despite similar energy intake.
To understand the mechanisms of food overconsumption in
humans, many studies have focused on ghrelin as an interest-
ing target in obesity and other eating disorders. Some studies
have shown that central ghrelin action stimulates the intake
of high-energy-dense palatable foods, and may play a key
role in the choice of highly palatable foods(37–39). In addition,
ghrelin administration stimulates food-seeking behaviour in
both human subjects and rodents(40). Subsequently, it has
been suggested that ghrelin regulates the extra-homeostatic
aspects of eating(41,42). The extra-homeostatic factors are
increased with food palatability and energy content, and may
result in overconsumption of food and then in obesity(42).
Ghrelin is now recognised as a key peptide in hedonic signal-
ling of food and possibly in the concept of food addic-
tion(39–42). In a recent series of experiments, Dickson and
8
journals.cambridge.org/jns
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/jns.2014.4
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 21:49:47, subject to the Cambridge Core terms of use, available at
her group(42) used a rat model to assess the role of ghrelin in
food reward. The speciﬁc role of endogenous ghrelin in food
reward was conﬁrmed by showing that the injection of a ghre-
lin receptor antagonist decreased the motivation of rats to
obtain sucrose pellets. They showed an impact of chronic cen-
tral ghrelin treatment on the gene expression of dopaminergic
and cholinergic receptors in key reward nodes of the central
nervous system. Hence, they underlined the potential role of
ghrelin as a therapeutic target to suppress overeating of
high-energy-dense foods in human subjects(42). In the present
study, the absence of AG suppression after an intravenous
load of ARG or glucose may suggest that some nutrients
unpredictably might not promote satiation in overweight
cats, but the role of ghrelin in food reward has never been
documented in this species.
Despite its key role in glucose homeostasis(15,16), surprisingly
no variation of amylin was observed after the glucose or ARG
load. However, after the TAG load, there was an increase in
amylin concentration, showing similar variations to insulin.
In human subjects with impaired glucose tolerance, amylin
release after a glucose load was decreased(43). It has also
been suggested that an altered ratio between amylin and insulin
secretion encourages abnormal feeding behaviour under some
conditions, such as type 1 diabetes or later stages of type 2 dia-
betes mellitus(16); if such a mechanism were relevant in over-
weight cats, the discrepancy observed between amylin and
insulin secretion may be one of the factors involved in the dys-
regulation of satiation and in BW increase in overweight cats.
As ghrelin modulates lactotroph secretion in human subjects
and animals(44,45), we hoped to demonstrate a relationship
between AG and PRL secretion. Nevertheless, in the present
study, we failed to observe such a relationship after a nutrient
load.
Some limitations appeared in the present study. We used a
small number of cats with large inter-individual variations.
Nevertheless, as all the cats underwent all the testing sessions,
this increased the statistical power of the study due to
intra-individual comparisons. Another drawback was that we
did not compare the endocrine response in normal-weight
and overweight cats, and responses would probably be differ-
ent as we previously noted(23) after a meal. The description of
changes in behaviour associated with the nutrient load would
be of great interest but we did not have a speciﬁc test to val-
idate our observations; hence further studies are needed to
associate clinical behaviour with laboratory work.
In conclusion, the present study showed that an intrave-
nous bolus of glucose or ARG increases glucose, insulin and
ghrelin responses in overweight cats. The results suggest a
signiﬁcant role for ghrelin in the control of glucose homeo-
stasis in this species, as in humans or rodents. Except for
with the TAG bolus, no suppression of ghrelin was observed
during the 100 min of the test. The absence of AG suppres-
sion after an intravenous load of ARG or glucose suggests:
(1) that some nutrients unexpectedly may not promote sati-
ation in overweight cats; and (2) a possible role for ghrelin
in food-reward mechanisms in the feline species. However,
the role of ghrelin in food reward remains to be assessed
in cats.
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